team-Iqbal-Hussain

Iqbal Hussain LLB

General Counsel

Iqbal Hussain, LLB, is General Counsel of Centessa Pharmaceuticals and is responsible for the leadership of our Legal, Compliance, IP and Corporate functions.

Prior to joining Centessa, Iqbal served as a Partner in the Global Corporate Group at Reed Smith, LLP, where he led the life sciences transactional practice across EMEA from September 2019 to January 2021.

Before joining Reed Smith, Iqbal was Legal Director for Mergers and Acquisitions at Johnson & Johnson. From February 2014 to August 2019, he was Senior Counsel and a member of the leadership team at the Johnson & Johnson EMEA Innovation Centre in London.

Iqbal began his career at Slaughter and May where he advised clients on public and private mergers and acquisitions. Iqbal was a Senior Associate in the Corporate Mergers and Acquisitions team at Ropes & Gray, LLP.

Iqbal received an LLB from the University of Sheffield in 2004.

Scroll to Top
;
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B